Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2019

Open Access 01-12-2019 | Rectal Cancer | Review

Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)

Authors: Jian Li, Ying Yuan, Fan Yang, Yi Wang, Xu Zhu, Zhenghang Wang, Shu Zheng, Desen Wan, Jie He, Jianping Wang, Yi Ba, Chunmei Bai, Li Bai, Wei Bai, Feng Bi, Kaican Cai, Muyan Cai, Sanjun Cai, Gong Chen, Keneng Chen, Lin Chen, Pengju Chen, Pan Chi, Guanghai Dai, Yanhong Deng, Kefeng Ding, Qingxia Fan, Weijia Fang, Xuedong Fang, Fengyi Feng, Chuangang Fu, Qihan Fu, Yanhong Gu, Yulong He, Baoqing Jia, Kewei Jiang, Maode Lai, Ping Lan, Enxiao Li, Dechuan Li, Jin Li, Leping Li, Ming Li, Shaolei Li, Yexiong Li, Yongheng Li, Zhongwu Li, Xiaobo Liang, Zhiyong Liang, Feng Lin, Guole Lin, Hongjun Liu, Jianzhong Liu, Tianshu Liu, Yunpeng Liu, Hongming Pan, Zhizhong Pan, Haiping Pei, Meng Qiu, Xiujuan Qu, Li Ren, Zhanlong Shen, Weiqi Sheng, Chun Song, Lijie Song, Jianguo Sun, Lingyu Sun, Yingshi Sun, Yuan Tang, Min Tao, Chang Wang, Haijiang Wang, Jun Wang, Shubin Wang, Xicheng Wang, Xishan Wang, Ziqiang Wang, Aiwen Wu, Nan Wu, Lijian Xia, Yi Xiao, Baocai Xing, Bin Xiong, Jianmin Xu, Jianming Xu, Nong Xu, Ruihua Xu, Zhongfa Xu, Yue Yang, Hongwei Yao, Yingjiang Ye, Yonghua Yu, Yueming Yu, Jinbo Yue, Jingdong Zhang, Jun Zhang, Suzhan Zhang, Wei Zhang, Yanqiao Zhang, Zhen Zhang, Zhongtao Zhang, Lin Zhao, Ren Zhao, Fuxiang Zhou, Jian Zhou, Jing Jin, Jin Gu, Lin Shen

Published in: Journal of Hematology & Oncology | Issue 1/2019

Login to get access

Abstract

The lungs are the second most common site of metastasis for colorectal cancer (CRC) after the liver. Rectal cancer is associated with a higher incidence of lung metastases compared to colon cancer. In China, the proportion of rectal cancer cases is around 50%, much higher than that in Western countries (nearly 30%). However, there is no available consensus or guideline focusing on CRC with lung metastases. We conducted an extensive discussion and reached a consensus of management for lung metastases in CRC based on current research reports and the experts’ clinical experiences and knowledge. This consensus provided detailed approaches of diagnosis and differential diagnosis and provided general guidelines for multidisciplinary therapy (MDT) of lung metastases. We also focused on recommendations of MDT management of synchronous lung metastases and initial metachronous lung metastases. This consensus might improve clinical practice of CRC with lung metastases in China and will encourage oncologists to conduct more clinical trials to obtain high-level evidences about managing lung metastases.
Appendix
Available only for authorised users
Literature
1.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRef
2.
Wang Z, Wang X, Yuan J, Zhang X, Zhou J, Lu M, Liu D, Li J, Shen L. Survival benefit of palliative local treatments and efficacy of different pharmacotherapies in colorectal cancer with lung metastasis: results from a large retrospective study. Clin Colorectal Cancer. 2018;17:e233–55.CrossRef
3.
Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59:1383–8.CrossRef
4.
Nordholm-Carstensen A, Krarup PM, Jorgensen LN, Wille-Jorgensen PA, Harling H, On behalf of Danish colorectal Cancer group. Occurrence and survival of synchronous pulmonary metastases in colorectal cancer: a nationwide cohort study. Eur J Cancer. 2014;50:447–56.CrossRef
5.
Chen Q, Liu Z, Cheng L, Song G, Sun X, Zheng R, Zhang S, Chen W. An analysis of incidence and mortality of colorectal cancer in China, 2003~2007. China Cancer. 2012;21:179–82 (In Chinese).
6.
Du L, Li H, Wang Y, Zhu C, Zheng R, Zhang S, Chen W, He J. Report of colorectal cancer incidence and mortality in China, 2013. Chin J Oncol. 2017;39:701–6 (In Chinese).
7.
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–17.CrossRef
8.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.CrossRef
9.
Prasanna T, Craft PS, Chua YJ, Karapetis CS, Gibbs P, Wong R, Tie J, Roder D, Price TJ, Padbury R, et al. The outcome of patients (pts) with metastatic colorectal cancer (mCRC) based on site of metastases (mets) and the impact of molecular markers and site of primary cancer on metastatic pattern. J Clin Oncol. 2017;35:abstr 3560.CrossRef
10.
Section of Gastrointestinal Surgery of Branch of Surgery of Chinese Medical Association, Section of Colorectal Surgery of Branch of Surgery of Chinese Medical Association, Chinese Society of Colon Cancer of China Anti-cancer Association, Chinese Society of Colon and Rectal Surgeons of Branch of Surgeons of Chinese Medical Doctor Association, Chinese Society of Tumor Metastasis of Branch of Anal Surgeons of Chinese Medical Doctor Association, Chinese Society of Colon and Rectal Tumors of Chinese Medical Doctor Association, Committee of Colorectal Experts of Chinese Society of Clinical Oncology, Professional Committee of Treatment for Colorectal Cancer Liver Metastasis of China International Exchange and Promotive Association for Medical and Healthcare. Guideline for the diagnosis and comprehensive treatment of colorectal cancer liver metastasis (2018 edition). Chin J Digest Surg. 2018;17:527–39 (In Chinese).
11.
Tampellini M, Ottone A, Bellini E, Alabiso I, Baratelli C, Bitossi R, Brizzi MP, Ferrero A, Sperti E, Leone F, et al. The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study. Oncologist. 2012;17:1430–8.CrossRef
12.
Watanabe K, Saito N, Sugito M, Ito M, Kobayashi A, Nishizawa Y. Incidence and predictive factors for pulmonary metastases after curative resection of colon cancer. Ann Surg Oncol. 2013;20:1374–80.CrossRef
13.
Moorcraft SY, Ladas G, Bowcock A, Chau I. Management of resectable colorectal lung metastases. Clin Exp Metastasis. 2016;33:285–96.CrossRef
14.
Nordholm-Carstensen A, Wille-Jorgensen PA, Jorgensen LN, Harling H. Indeterminate pulmonary nodules at colorectal cancer staging: a systematic review of predictive parameters for malignancy. Ann Surg Oncol. 2013;20:4022–30.CrossRef
15.
Nordholm-Carstensen A, Jorgensen LN, Wille-Jorgensen PA, Hansen H, Harling H. Indeterminate pulmonary nodules in colorectal-cancer: do radiologists agree? Ann Surg Oncol. 2015;22:543–9.CrossRef
16.
Chiang JM, Hsieh PS, Chen JS, Tang R, You JF, Yeh CY. Rectal cancer level significantly affects rates and patterns of distant metastases among rectal cancer patients post curative-intent surgery without neoadjuvant therapy. World J Surg Oncol. 2014;12:197.CrossRef
17.
Kim CH, Huh JW, Kim HR, Kim YJ. Indeterminate pulmonary nodules in colorectal cancer: follow-up guidelines based on a risk predictive model. Ann Surg. 2015;261:1145–52.CrossRef
18.
Brent A, Talbot R, Coyne J, Nash G. Should indeterminate lung lesions reported on staging CT scans influence the management of patients with colorectal cancer? Color Dis. 2007;9:816–8.CrossRef
19.
Baek SJ, Kim SH, Kwak JM, Cho JS, Shin JW, Amar AH, Kim J. Indeterminate pulmonary nodules in rectal cancer: a recommendation for follow-up guidelines. J Surg Oncol. 2012;106:481–5.CrossRef
20.
Jung EJ, Kim SR, Ryu CG, Paik JH, Yi JG, Hwang DY. Indeterminate pulmonary nodules in colorectal cancer. World J Gastroenterol. 2015;21:2967–72.CrossRef
21.
Zheng J, Shen D, Xue W. Rosai and Ackerman’s surgical pathology (tenth edition) (author: Juan Rosai). Beijing: Peking University Medical Press; 2014. (In Chinese)
22.
Hospital Authority of National Health and Family Planning Commission of the People’s Republic of China, Chinese Society of Oncology. Chinese protocol of diagnosis and treatment of colorectal cancer. Chin J Surg. 2018;56:241–58 (In Chinese).
23.
Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–48.CrossRef
24.
Cho S, Song IH, Yang HC, Jheon S. Prognostic factors of pulmonary metastasis from colorectal carcinoma. Interact Cardiovasc Thorac Surg. 2013;17:303–7.CrossRef
25.
Bolukbas S, Sponholz S, Kudelin N, Eberlein M, Schirren J. Risk factors for lymph node metastases and prognosticators of survival in patients undergoing pulmonary metastasectomy for colorectal cancer. Ann Thorac Surg. 2014;97:1926–32.CrossRef
26.
Borasio P, Gisabella M, Bille A, Righi L, Longo M, Tampellini M, Ardissone F. Role of surgical resection in colorectal lung metastases: analysis of 137 patients. Int J Color Dis. 2011;26:183–90.CrossRef
27.
Chao YK, Chang HC, Wu YC, Liu YH, Hsieh MJ, Chiang JM, Liu HP. Management of lung metastases from colorectal cancer: video-assisted thoracoscopic surgery versus thoracotomy--a case-matched study. Thorac Cardiovasc Surg. 2012;60:398–404.CrossRef
28.
Chen F, Hanaoka N, Sato K, Fujinaga T, Sonobe M, Shoji T, Sakai H, Miyahara R, Bando T, Okubo K, et al. Prognostic factors of pulmonary metastasectomy for colorectal carcinomas. World J Surg. 2009;33:505–11.CrossRef
29.
Cho JH, Kim S, Namgung M, Choi YS, Kim HK, Zo JI, Shim YM, Kim J. The prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer. World J Surg Oncol. 2015;13:222.CrossRef
30.
Cho JH, Hamaji M, Allen MS, Cassivi SD, Nichols FC 3rd, Wigle DA, Shen KR, Deschamps C. The prognosis of pulmonary metastasectomy depends on the location of the primary colorectal cancer. Ann Thorac Surg. 2014;98:1231–7.CrossRef
31.
Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2013;20:572–9.CrossRef
32.
Hamaji M, Cassivi SD, Shen KR, Allen MS, Nichols FC, Deschamps C, Wigle DA. Is lymph node dissection required in pulmonary metastasectomy for colorectal adenocarcinoma? Ann Thorac Surg. 2012;94:1796–800.CrossRef
33.
Iida T, Nomori H, Shiba M, Nakajima J, Okumura S, Horio H, Matsuguma H, Ikeda N, Yoshino I, Ozeki Y, et al. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg. 2013;257:1059–64.CrossRef
34.
Iizasa T, Suzuki M, Yoshida S, Motohashi S, Yasufuku K, Iyoda A, Shibuya K, Hiroshima K, Nakatani Y, Fujisawa T. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg. 2006;82:254–60.CrossRef
35.
Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg. 2004;91:112–20.CrossRef
36.
Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84:324–38.CrossRef
37.
Pfannschmidt J, Muley T, Hoffmann H, Dienemann H. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg. 2003;126:732–9.CrossRef
38.
Riquet M, Foucault C, Cazes A, Mitry E, Dujon A, Le Pimpec Barthes F, Medioni J, Rougier P. Pulmonary resection for metastases of colorectal adenocarcinoma. Ann Thorac Surg. 2010;89:375–80.CrossRef
39.
Saito Y, Omiya H, Kohno K, Kobayashi T, Itoi K, Teramachi M, Sasaki M, Suzuki H, Takao H, Nakade M. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg. 2002;124:1007–13.CrossRef
40.
Vogelsang H, Haas S, Hierholzer C, Berger U, Siewert JR, Präuer H. Factors influencing survival after resection of pulmonary metastases from colorectal cancer. Br J Surg. 2004;91:1066–71.CrossRef
41.
Watanabe K, Nagai K, Kobayashi A, Sugito M, Saito N. Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg. 2009;96:1058–65.CrossRef
42.
Younes RN, Abrao F, Gross J. Pulmonary metastasectomy for colorectal cancer: long-term survival and prognostic factors. Int J Surg. 2013;11:244–8.CrossRef
43.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.CrossRef
44.
Ibrahim T, Tselikas L, Yazbeck C, Kattan J. Systemic versus local therapies for colorectal cancer pulmonary metastasis: what to choose and when? J Gastrointest Cancer. 2016;47:223–31.CrossRef
45.
Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378:1177–88.CrossRef
46.
Iveson T, Kerr R, Saunders M, Hollander N, Tabernero J, Haydon A, Glimelius B, Harkin A, Scudder C, Boyd K, et al. Updated results of the SCOT study: an international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer. Ann Oncol. 2017;28:LBA22.CrossRef
47.
Nozawa H, Ishihara S, Kawai K, Hata K, Kiyomatsu T, Tanaka T, Nishikawa T, Otani K, Yasuda K, Sasaki K, et al. Characterization of conversion chemotherapy for secondary surgical resection in colorectal cancer patients with lung metastases. Oncology. 2017;92:135–41.CrossRef
48.
Li WH. Oncological outcome of unresectable lung metastases without extrapulmonary metastases in colorectal cancer. World J Gastroenterol. 2010;16:3318.CrossRef
49.
Martinelli E, Sforza V, Cardone C, Capasso A, Nappi A, Martini G, Napolitano S, Rachiglio AM, Normanno N, Cappabianca S, et al. Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. ESMO Open. 2017;2:e000177.CrossRef
50.
Hawkes EA, Ladas G, Cunningham D, Nicholson AG, Wassilew K, Barbachano Y, Ratnayake G, Rao S, Chau I. Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. BMC Cancer. 2012;12:326.CrossRef
51.
Subbiah IM, Blackmon SH, Correa AM, Kee B, Vaporciyan AA, Swisher SG, Eng C. Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. Oncotarget. 2014;5:6584–93.PubMedPubMedCentral
52.
Rama N, Monteiro A, Bernardo JE, Eugenio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors. Eur J Cardiothorac Surg. 2009;35:444–9.CrossRef
53.
Suzuki H, Kiyoshima M, Kitahara M, Asato Y, Amemiya R. Long-term outcomes after surgical resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg. 2015;99:435–40.CrossRef
54.
Zabaleta J, Aguinagalde B, Izquierdo JM, Bazterargui N, Laguna SM, Martin-Arruti M, Lobo C, Emparanza JI. The presence of mutations in the K-RAS gene does not affect survival after resection of pulmonary metastases from colorectal cancer. ISRN Surg. 2014;2014:157586.CrossRef
55.
Gonzalez M, Ris HB, Krueger T, Gervaz P. Colorectal cancer and thoracic surgeons: close encounters of the third kind. Expert Rev Anticancer Ther. 2012;12:495–503.CrossRef
56.
Ricco A, Davis J, Rate W, Yang J, Perry D, Pablo J, D'Ambrosio D, Sharma S, Sundararaman S, Kolker J, et al. Lung metastases treated with stereotactic body radiotherapy: the RSSearch(R) patient Registry’s experience. Radiat Oncol. 2017;12:35.CrossRef
57.
Osti MF, Carnevale A, Valeriani M, De Sanctis V, Minniti G, Cortesi E, Martelli M, Maurizi ER. Clinical outcomes of single dose stereotactic radiotherapy for lung metastases. Clin Lung Cancer. 2013;14:699–703.CrossRef
58.
Navarria P, Ascolese AM, Tomatis S, Cozzi L, De Rose F, Mancosu P, Alongi F, Clerici E, Lobefalo F, Tozzi A, et al. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014;9:91.CrossRef
59.
de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B, Palussiére J. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol. 2015;26:987–91.CrossRef
60.
Mise Y, Kopetz S, Mehran RJ, Aloia TA, Conrad C, Brudvik KW, Taggart MW, Vauthey JN. Is complete liver resection without resection of synchronous lung metastases justified? Ann Surg Oncol. 2015;22:1585–92.CrossRef
61.
Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, Giovagnoni A. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010;31:19–31.CrossRef
62.
Bartolotta TV, Taibbi A, Midiri M, La Grutta L, De Maria M, Lagalla R. Characterisation of focal liver lesions undetermined at grey-scale US: contrast-enhanced US versus 64-row MDCT and MRI with liver-specific contrast agent. Radiol Med. 2010;115:714–31.CrossRef
63.
Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257:674–84.CrossRef
64.
Kim S, Kim HK, Cho JH, Choi YS, Kim K, Kim J, Zo JI, Shim YM, Heo JS, Lee WY, et al. Prognostic factors after pulmonary metastasectomy of colorectal cancers: influence of liver metastasis. World J Surg Oncol. 2016;14:201.CrossRef
65.
Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17:1225–39.CrossRef
66.
Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol. 2012;23:1687–93.CrossRef
Metadata
Title
Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)
Authors
Jian Li
Ying Yuan
Fan Yang
Yi Wang
Xu Zhu
Zhenghang Wang
Shu Zheng
Desen Wan
Jie He
Jianping Wang
Yi Ba
Chunmei Bai
Li Bai
Wei Bai
Feng Bi
Kaican Cai
Muyan Cai
Sanjun Cai
Gong Chen
Keneng Chen
Lin Chen
Pengju Chen
Pan Chi
Guanghai Dai
Yanhong Deng
Kefeng Ding
Qingxia Fan
Weijia Fang
Xuedong Fang
Fengyi Feng
Chuangang Fu
Qihan Fu
Yanhong Gu
Yulong He
Baoqing Jia
Kewei Jiang
Maode Lai
Ping Lan
Enxiao Li
Dechuan Li
Jin Li
Leping Li
Ming Li
Shaolei Li
Yexiong Li
Yongheng Li
Zhongwu Li
Xiaobo Liang
Zhiyong Liang
Feng Lin
Guole Lin
Hongjun Liu
Jianzhong Liu
Tianshu Liu
Yunpeng Liu
Hongming Pan
Zhizhong Pan
Haiping Pei
Meng Qiu
Xiujuan Qu
Li Ren
Zhanlong Shen
Weiqi Sheng
Chun Song
Lijie Song
Jianguo Sun
Lingyu Sun
Yingshi Sun
Yuan Tang
Min Tao
Chang Wang
Haijiang Wang
Jun Wang
Shubin Wang
Xicheng Wang
Xishan Wang
Ziqiang Wang
Aiwen Wu
Nan Wu
Lijian Xia
Yi Xiao
Baocai Xing
Bin Xiong
Jianmin Xu
Jianming Xu
Nong Xu
Ruihua Xu
Zhongfa Xu
Yue Yang
Hongwei Yao
Yingjiang Ye
Yonghua Yu
Yueming Yu
Jinbo Yue
Jingdong Zhang
Jun Zhang
Suzhan Zhang
Wei Zhang
Yanqiao Zhang
Zhen Zhang
Zhongtao Zhang
Lin Zhao
Ren Zhao
Fuxiang Zhou
Jian Zhou
Jing Jin
Jin Gu
Lin Shen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2019
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-019-0702-0

Other articles of this Issue 1/2019

Journal of Hematology & Oncology 1/2019 Go to the issue

Review

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

Review

Targeting cancers through TCR-peptide/MHC interactions

Rapid communication

Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma

Review

Target selection for CAR-T therapy

Review

Molecular pathogenic pathways in extranodal NK/T cell lymphoma

Review

Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits